Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary

Strategic focus and therapeutic innovation

• Focused on improving mitochondrial health and protecting neuron function to address neurodegenerative diseases, especially ALS, MS, and Parkinson's.

• Pioneering catalytic nanotherapeutics, specifically a gold nanocrystal suspension (Au8), taken orally and designed to cross the blood-brain barrier.

• Asset demonstrates a strong safety profile with over 900 participant-years and no serious adverse events related to the drug.

• Multiple patents and trade secrets protect the technology, with ongoing regulatory discussions.

Clinical trial results and regulatory engagement

• Completed several phase II programs in ALS (HEALEY, RESCUE) and MS (Visionary), with ongoing translational work in Parkinson's and progressive MS.

• Missed primary endpoints in ALS trials but achieved significant secondary outcomes, including survival and clinical worsening improvements.

• Statistically significant neurofilament biomarker improvements observed, correlating with survival benefits in high-risk patients.

• Expanded access and compassionate use protocols show significant survival benefits compared to natural history controls.

• Ongoing and upcoming FDA interactions may enable accelerated approval based on neurofilament as a surrogate marker.

Multiple sclerosis program and future plans

• MS study (Visionary) showed promising secondary outcomes in cognition and fine motor skills, with long-term improvements in vision and cognitive function.

• MRI and biomarker data support remyelination and neural protection, with recent significant correlation data presented at a major neurology conference.

• Planning an end-of-phase II meeting with the FDA for MS, with partnering discussions underway to support further clinical development.